Literature DB >> 11959597

Activities of new fluoroquinolones, ketolides, and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000.

Andrea S Gershon1, Joyce C S de Azavedo, Allison McGeer, Krystyna I Ostrowska, Deirdre Church, Daryl J Hoban, Godfrey K M Harding, Karl Weiss, Lewis Abbott, Fiona Smaill, Marie Gourdeau, Gilles Murray, Donald E Low.   

Abstract

The rates of nonsusceptibility to penicillin, erythromycin, and clindamycin of 191 blood culture isolates of viridans group streptococci collected from across Canada in 2000 were 36, 42, and 10%, respectively. Although 8% of the strains were resistant to ciprofloxacin (MIC >or= 4 microg/ml), the MICs of gemifloxacin, BMS 284756, telithromycin, and ABT 773 at which 90% of the strains were inhibited were 0.06, 0.06, 0.12, and 0.03 microg/ml, respectively.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11959597      PMCID： PMC127166          DOI： 10.1128/AAC.46.5.1553-1556.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada.

Authors:  J C de Azavedo; L Trpeski; S Pong-Porter; S Matsumura; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  False resistance to imipenem with a microdilution susceptibility testing system.

Authors:  E J O'Rourke; K G Lambert; K C Parsonnet; A B Macone; D A Goldmann
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

3.  High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients.

Authors:  A Marron; J Carratalà; F Alcaide; A Fernández-Sevilla; F Gudiol
Journal:  J Antimicrob Chemother       Date:  2001-01       Impact factor: 5.790

4.  Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients.

Authors:  M Venditti; P Baiocchi; C Santini; C Brandimarte; P Serra; G Gentile; C Girmenia; P Martino
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

5.  Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer.

Authors:  G Fleischhack; C Hartmann; A Simon; B Wulff; W Havers; G Marklein; C Hasan; U Bode
Journal:  J Antimicrob Chemother       Date:  2001-06       Impact factor: 5.790

6.  Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer.

Authors:  J Carratalá; F Alcaide; A Fernández-Sevilla; X Corbella; J Lińares; F Gudiol
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

7.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States.

Authors:  G V Doern; M J Ferraro; A B Brueggemann; K L Ruoff
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

9.  Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin.

Authors:  P H McWhinney; S Patel; R A Whiley; J M Hardie; S H Gillespie; C C Kibbler
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

10.  Antibiotic susceptibility of streptococci isolated from blood from neutropenic patients.

Authors:  D Piérard; A de Meyer; S Lauwers
Journal:  Pathol Biol (Paris)       Date:  1994-05
View more
  4 in total

1.  New species genetic approach to identify strains of mitis group streptococci that are donors of rifampin resistance to Streptococcus pneumoniae.

Authors:  María-José Ferrándiz; Carmen Ardanuy; Josefina Liñares; Luz Balsalobre; María Teresa García; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

2.  Antimicrobial susceptibility patterns among viridans group streptococcal isolates from infective endocarditis patients from 1971 to 1986 and 1994 to 2002.

Authors:  Rajesh M Prabhu; Kerryl E Piper; Larry M Baddour; James M Steckelberg; Walter R Wilson; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  In vitro activity of telithromycin against viridans group streptococci and Streptococcus bovis isolated from blood: antimicrobial susceptibility patterns in different groups of species.

Authors:  Iciar Rodríguez-Avial; Carmen Rodríguez-Avial; Esther Culebras; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

4.  Clinical features and antimicrobial susceptibility of oral bacteria isolated from the blood cultures of patients with infective endocarditis.

Authors:  Keigo Maeda; Yuzo Hirai; Masanori Nashi; Shinsuke Yamamoto; Naoki Taniike; Toshihiko Takenobu
Journal:  J Dent Sci       Date:  2021-09-28       Impact factor: 3.719
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.